News Column

Findings from North Dakota State University Reveals New Findings on Pancreatic Cancer (MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient...

August 13, 2014



Findings from North Dakota State University Reveals New Findings on Pancreatic Cancer (MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer)

By a News Reporter-Staff News Editor at Biotech Week -- Investigators publish new report on Oncology. According to news reporting originating from Fargo, North Dakota, by NewsRx correspondents, research stated, "Significant differences in biochemical parameters between normal and tumor tissues offer an opportunity to chemically design drug carriers which respond to these changes and deliver the drugs at the desired site. For example, overexpression of the matrix metalloproteinase-9 (MMP-9) enzyme in the extracellular matrix of tumor tissues can act as a trigger to chemically modulate the drug delivery from the carriers."

Our news editors obtained a quote from the research from North Dakota State University, "In this study, we have synthesized an MIVIP-9-cleavable, collagen mimetic lipopeptide which forms nanosized vesicles with the POPC, POPE-SS-PEG, and cholesteryl-hemisuccinate lipids. The lipopeptide retains the triple-helical conformation when incorporated into these nanovesicles. The PEG groups shield the substrate lipopeptides from hydrolysis by MMP-9. However, in the presence of elevated glutathione levels, the PEG groups are reductively removed, exposing the lipopeptides to MMP-9. The resultant peptide-bond cleavage disturbs the vesicles' lipid bilayer, leading to the release of encapsulated contents. These PEGylated nanovesicles are capable of encapsulating the anticancer drug gemcitabine with 50% efficiency. They were stable in physiological conditions and in human serum. Effective drug release was demonstrated using the pancreatic ductal carcinoma cells (PANC-1 and MIAPaCa-2) in two-dimensional and three-dimensional 'tumor-like' spheroid cultures."

According to the news editors, the research concluded: "A reduction in tumor growth was observed after intravenous administration of the gemcitabine-encapsulated nanovesicles in the xenograft model of athymic, female nude mice."

For more information on this research see: MMP-9 Responsive PEG Cleavable Nanovesicles for Efficient Delivery of Chemotherapeutics to Pancreatic Cancer. Molecular Pharmaceutics, 2014;11(7):2390-2399. Molecular Pharmaceutics can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; Molecular Pharmaceutics - www.pubs.acs.org/journal/mpohbp)

The news editors report that additional information may be obtained by contacting P.S. Kulkarni, North Dakota State University, Dept. of Biol Sci, Fargo, ND 58102, United States. Additional authors for this research include M.K. Haldar, R.R. Nahire, P. Katti, A.H. Ambre, W.W. Muhonen, J.B. Shabb, S.K.R. Padi, R.K. Singh, P.P. Borowicz, D.K. Shrivastava, K.S. Katti, K. Reindl, B. Guo and S. Mallik (see also Oncology).

Keywords for this news article include: Fargo, Oncology, North Dakota, Lipopeptides, Nanovesicles, United States, Nanotechnology, Gastroenterology, Pancreatic Cancer, Pancreatic Neoplasms, Emerging Technologies, North and Central America

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters